Objective: To compare prenatal maternal hepatitis B virus (HBV) screening and infant vaccination strategies to inform policy on HBV prevention in Sub-Saharan Africa.
| INTRODUCTION
More than 360 million people worldwide are chronically infected with hepatitis B virus (HBV), which is a frequent cause of liver disease and hepatocellular carcinoma; infection with HBV is endemic in Sub-Saharan Africa, where the seroprevalence is 10%-15%.
1 Vertical
(mother-to-child) transmission of HBV occurs via exposure to infected blood and body fluids during delivery, and is strongly associated with the maternal viral load (measured as the concentration of HBV DNA) and the presence of the HBV e antigen. 2 As the likelihood of chronic HBV infection is inversely related to age at the time of exposure, it is crucial that steps are taken to prevent vertical transmission.
Vaccination against HBV is both safe and effective. Most cases of vertical transmission (75%-95%) can be prevented by vaccination alone if a monovalent birth-dose HBV vaccine is followed by completion of at least three-doses of a Hepatitis B vaccine in infancy. Haemophilus influenzae) that is given at 6, 10, and 14 weeks of age.
Reasons given to support lack of vaccination at birth include cost, low birth rates in health facilities, insufficient data on the relative contribution of vertical versus horizontal transmission to overall prevalence rates for pediatric HBV, and logistic challenges. Information regarding the cost and efficacy of various HBV prevention strategies is urgently needed to guide national vaccination policies in Sub-Saharan Africa. The aim of the present study was to compare three different intervention strategies in terms of the number of HBV infections prevented and the costs involved.
| MATERIALS AND METHODS
A decision analytic model was created to assess strategies for HBV prevention in Sub-Saharan Africa, with a focus on Cameroon. Three intervention strategies were compared with a reference strategy. The details of these four strategies are outlined in Figure 1 . Institutional review board approval was not required for the present study owing to the literature-based nature of the design.
The primary outcomes were the number of HBV infections acquired by 10 years of age (capturing both vertical transmission and horizontal transmission during childhood) and the cost per HBV infection prevented.
The model assumed that prenatal care, perinatal care, and testing for the presence of HBV surface antigen were accessible for healthcare facility deliveries. Additional case-finding costs to identify pregnancies or births were not included in the model. Furthermore, the model assumed 100% compliance with birth-dose HBV vaccination and completion of the pentavalent series. Any partial protection provided by an incomplete series was not modeled. The present model also assumed that the pentavalent vaccine series was ineffective for the prevention of vertical transmission because it was not provided until 6 weeks after delivery. Figure 2 shows the branch of the decision analytic model for strategy 2 (no maternal HBV screening; universal birth-dose HBV vaccine plus pentavalent vaccine) as an example.
Base prevalence estimates were derived from published data collected in Cameroon and from ranges that were representative of search combined the terms "Hepatitis B" and "Cameroon", "Africa", or "developing countries" with each of the following words: "vaccination", "incidence", "horizontal transmission", "vertical transmission", and "efficacy". The bibliographies of the identified sources were also searched.
The probability ranges for the sensitivity analysis were defined as the highest and lowest values available in the literature review. One in every 10 children were assumed to have protective levels of antibodies against the HBV surface antigen following birth-dose vaccination, therefore decreasing the rate of horizontal infection by 10%. 15 Robust data were not available to determine the protective effect against vertical transmission of birth-dose HBV vaccination that is not followed by additional doses. Therefore, if a modeled child only received the birth dose vaccination that was not followed by any additional vaccines, the model included a wide range of protection from vertical transmission of HBV from 5% to 50%.
Cost estimates for HBV vaccines and prenatal screening tests were based on representative information collected by the Cameroon Baptist Convention Health Services HBV vaccination program and included costs for injection supplies, delivery, and storage (Table 1 ). All costs are reported US dollars at the 2015 exchange rate. The time value of money was not considered because all costs were incurred in the same year in this model. The present analysis used willingness-to-pay (WTP) thresholds to define the maximum cost that a society is willing to pay for each incremental improvement in outcome. The WTP threshold for vaccination among low-and middle-income countries ranges from less than $100 to greater than $2000, depending on the country, severity of infection, and transmissibility. 21 The average WTP threshold for HBV prevention is not well-documented in Sub-Saharan Africa; therefore, a range of $100-$2000 was used in the present study.
The analysis was performed using TreeAge Pro 2009 (TreeAge Software, Williamstown, MA, USA). Owing to inconsistencies in the baseline assumptions and probability ranges in the literature review, sensitivity analyses were applied. The estimates of probability, and cost were varied across the probability range, alone and in combination. Monte
Carlo simulation was also used to simultaneously vary all values at random over multiple iterations. This allowed for estimates of the frequency that the conclusion of the model was concordant with the base case analysis. A total of 10 000 Monte Carlo simulations were performed.
| RESULTS
The results of the decision analysis model are presented in Table 2 In one-way, two-way, and three-way analyses, the preferred strategy when considering cost per infection prevented was sensitive to both the proportion of children who completed the pentavalent vaccine series and the maternal seroprevalence of HBV (Fig. 3) . Strategy 1 was preferred at a seroprevalence of less than 6%; however, as the seroprevalence increased to greater than 6%, a strategy that included the birth-dose HBV vaccine became the preferred option. Strategy 3 was the preferred option only when the proportion of children who completed the pentavalent series exceeded 80% and the seroprevalence of HBV was less than 13%. In the majority of situations, universal birth dose HBV is the preferred strategy at a WTP threshold of $150 (Fig. 3) .
The other major factor determining the optimum intervention was the WTP threshold (Fig. 4) . As this value increased to $150, either strategy 2 or strategy 3 became the preferred option. By contrast, strategy 1 was the preferred option at a WTP threshold of less than $150.
| DISCUSSION
The present study examined the cost and efficacy of three intervention strategies to prevent HBV infection before age 10 years in a Sub-Saharan setting. The analysis required creation of a decision tree, in which each branch represented a different vaccination schedule.
The benefit of this approach was that it enabled consideration of a range of HBV prevalence and vaccination regimens to ensure that the results obtained were applicable to a large geographic region.
The present study indicated that the addition of a universal birthdose HBV vaccine to the pentavalent vaccine (strategy 2) prevented the greatest number of additional HBV infections and was the preferred strategy at a WTP threshold of $150 per infection prevented when the maternal HBV seroprevelance was greater than 6%. The prevalence of T A B L E 2 Infections and costs associated with the hepatitis B virus prevention strategies. The pentavalent vaccine comprised HBV, diphtheria, tetanus, pertussis, and Haemophilus influenzae.
F I G U R E 3 Sensitivity analysis for the three intervention strategies at a willingness to pay threshold of $150. The pentavalent vaccine comprised HBV, diphtheria, tetanus, pertussis, and Haemophilus influenzae. Abbreviation: HBV, hepatitis B virus.
HBV infection during pregnancy in Sub-Saharan Africa is 5%-13%
and so is often higher than the 6% cutoff value identified in the present study. Targeted that, in Africa, there is a higher HBV acquisition risk after-instead of during-the perinatal period. 4, 17 Owing to this gap in the literature, the present study estimated rates of vertical and horizontal transmission on the basis of the available data, 4,7 and assumed a broad range of horizontal transmission (5%-30%). However, the results obtained were not sensitive to this wide range.
Another limitation was the lack of information regarding the relative efficacy of HBV vaccination initiated at birth versus at 6 weeks.
One randomized controlled study conducted in Cote d'Ivoire addressed this question. 16 The findings suggested that birth-dose vaccination was associated with a reduction of up to 50% in infant HBV infection when compared to a vaccination strategy started at 6 weeks.
16
However, this difference was not statistically significant, possibly owing to the small number of participants. A study that assessed the independent impact of a birth-dose HBV vaccination program in China showed that greater than 50% of the reduction in HBV prevalence could be attributed to this intervention.
24
The present study did not account for the cost of identifying HBVexposed infants who were born outside of a healthcare facility. This discrepacy therefore underestimated the costs of universal administration of the HBV vaccine at birth. The charge to patients in the hospital in Cameroon was at least $4-$5. Greater than 60% of all births in Cameroon occur in a healthcare facility and this coverage is increasing. 25 The present study obtained vaccine costs from local hospitals, which incorporated the cold-chain costs. Provision of the birth-dose HBV vaccine to women undergoing home deliveries would therefore add both cold-chain and case-finding costs.
The incremental effects of each dose of the pentavalent vaccine were not modeled in the present study owing to a lack of base data estimates. This discrepancy would have a minimal effect in many Sub-Saharan countries because approximately 90% of all infants successfully complete the pentavalent vaccine series. However, it is a potential issue for countries in which the completion rates are just 13%-30%. lack immunogenicity at this time point. Consequently, the present study assumed that the full pentavalent series should still be given after the birth dose (i.e. four doses of HBV vaccine in total rather than three).
The present study did not consider the long-term healthcare costs associated with chronic HBV infection because country-specific data were lacking. In many Sub-Saharan countries, limited care is available to patients with chronic HBV infection. The present study therefore determined only the cost per HBV infection prevented rather than the cost per quality-adjusted life year. Nonetheless, the birth-dose HBV vaccine was expected to remain cost-effective even when considering the cost per quality-adjusted life year.
In conclusion, the current findings support WHO recommendations for universal birth-dose HBV vaccine administration irrespective of the maternal HBV status. 1 Use of this approach within a healthcare facility is below typical WTP thresholds and so offers a cost-effective intervention strategy for low-and middle-income countries working to reduce rates of HBV infection. Further research is needed to determine the WTP threshold as there is no published data on WTP thresholds for HBV.
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